$1-per-pill alternative to Turing drug gets 'overwhelming' response: Imprimis CEO

Imprimis ($IMMY) CEO Mark Baum says response has been "overwhelming" to his company's $1-per-pill alternative to toxoplasmosis drug Daraprim, from the now-notorious Turing Pharmaceuticals, which raised its pill price to $750 each from $13.50 earlier this year. Report

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.